Vera Belaoussoff
Corporate Officer/Principal bei CellAegis Devices, Inc.
Aktive Positionen von Vera Belaoussoff
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
CellAegis Devices, Inc.
 CellAegis Devices, Inc. Electronic Equipment/InstrumentsElectronic Technology CellAegis Devices, Inc. develops device for the treatment of cardiac patients. . It offers autoRIC Device, an automated noninvasive device that provides point of care delivery of remote ischemic conditioning. The company was founded by John Berton, Andrew N. Redington and Christopher Caldarone and is headquartered in Toronto, Canada. | Corporate Officer/Principal | - | - |
Karriereverlauf von Vera Belaoussoff
Ehemalige bekannte Positionen von Vera Belaoussoff
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 09.10.2009 | - |
Ausbildung von Vera Belaoussoff
| York University | Graduate Degree |
| University of Manitoba | Undergraduate Degree |
Statistik
International
| Kanada | 4 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Electronic Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
CellAegis Devices, Inc.
CellAegis Devices, Inc. Electronic Equipment/InstrumentsElectronic Technology CellAegis Devices, Inc. develops device for the treatment of cardiac patients. . It offers autoRIC Device, an automated noninvasive device that provides point of care delivery of remote ischemic conditioning. The company was founded by John Berton, Andrew N. Redington and Christopher Caldarone and is headquartered in Toronto, Canada. | Electronic Technology |
- Börse
- Insiders
- Vera Belaoussoff
- Erfahrung
